In this episode of The OncoloGIST, myeloma experts discuss the abstracts they most anticipated at IMS 2026, including EXCALIBER-RRMM and PERSEUS.
Jessica Encinas Mayoral, PhD
Advertisement
Articles by Jessica Encinas Mayoral, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
2
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
3
Vilamakitug Meets Phase 2 Efficacy Criterion in Refractory Metastatic Colorectal Cancer
4
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
5